X

News

Dr. Yvonne Chen’s Work with ImmPACT Bio Approved by FDA

January 26, 2023 (Sourced from PR Newswire)

ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced clearance of its first Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for IMPT-314, a bispecific “OR-Gate” autologous CAR T-cell therapy targeting the B-cell antigens CD19 and CD20. IMPT-314 will be studied in a Phase 1/2 clinical trial in patients with aggressive B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL).

“Based on the pioneering work of Yvonne Chen, Ph.D., associate professor at the University of California, Los Angeles (UCLA), this CD19/CD20-directed bispecific CAR has demonstrated clinically meaningful and differentiated results in an ongoing investigator-led study at UCLA. Principal investigator Sarah Larson, M.D., studied patients with non-Hodgkin lymphoma (NHL), including various subtypes of aggressive B-cell lymphoma, DLBCL, non-indolent or refractory follicular lymphoma (FL), and mantle cell lymphoma (MCL). Data from the study demonstrated 90 percent of patients (9/10) had an objective response with 70 percent (7/10) of patients achieving a durable complete response (CR). Of note, no patients had neurotoxicity, also known as immune effector cell-associated neurotoxicity syndrome (ICANS). Patients had Grade 1 or no cytokine release syndrome (CRS). Median follow-up was more than 20 months and median progression-free survival (PFS) is 18.2 months. These results from the first 10 evaluable patients were recently published in Cancer Discovery. The UCLA study continues to enroll additional patients.

“Dr. Chen designed this bispecific CAR to address antigen escape, which is a key challenge for current approved CD19 therapies for hematological malignancies,” said Dr. Larson. “We tested this anti-CD19/CD20 CAR-T cell therapy in patients with relapsed or refractory NHL and are encouraged about the potential of this therapy for patients.”

To read more about this news, please see the article here.

 

Manish Butte Lab ‘SymphNode’ Device Featured in Nature Biomedical Engineering

January 25, 2023 (Sourced from UCLA Newsroom)

An interdisciplinary UCLA research team, which includes Dr. Manish Butte’s lab, reports encouraging results in laboratory studies testing a tiny implantable device they call a SymphNode, which is designed to keep regulatory T cells in check only in the area around a tumor while summoning and strengthening tumor-fighting cells. The device was shown to drive tumors into remission, eliminate metastasis, prevent the growth of new tumors and result in longer survival in mice.

Their findings are published today in Nature Biomedical Engineering.

“Getting rid of regulatory T cells within the tumor seems to be transformative,” said co–corresponding author Manish Butte, UCLA’s E. Richard Stiehm Professor of Pediatric Allergy, Immunology and Rheumatology and a member of the California NanoSystems Institute at UCLA. “Every solid tumor is crammed with these cells, and they’re why 91% of cancer deaths occur from solid tumors. They’re probably limiting our ability to cure the cancer in the first place.”

The SymphNode is a tiny biodegradable sponge about the size of a pencil eraser that is made from alginate, the same jiggly polymer used to thicken pudding. When surgically implanted directly next to a tumor, the sponge stimulates the body’s immune response against cancer in multiple ways: It slowly releases a drug that blocks the regulatory T cells in the tumor. At the same time, it attracts and beefs up the T cells that kill tumors. The material that the device is made of resembles a lymph node, a welcoming setting for cancer-fighting cells, and has pores lined with antibodies that further activate those cells.

For further reading, please visit the article link here.

 

   

 

EndpointsNews Features Dr. Lili Yang in their 2022 Women in Biopharma’22 Report

December 19, 2022

Over the past three years, Endpoints News has spotlighted 60 women who have blazed trails and supercharged R&D across the biopharma world. MIMG Faculty Dr. Lili Yang is one of the latest recipients to be honored on this list for 2022. This profile recognizes her accomplishment in biotech entrepreneurship. In particular, Yang’s recent biotech startup, Appia Bio, which is based on her research in UCLA MIMG labs.

For more information, please read here: https://endpts.com/special-report-meet-20-extraordinary-women-who-are-supercharging-biopharma-rd/

 

Dr. Anthony Covarrubias Named New DEI Advisor of MBIDP

Dec 15, 2022

We are excited to announce that MIMG Faculty Member Dr. Anthony Covarrubias will be joining the UCLA Molecular Biology Interdepartmental Doctoral Program. 

Anthony Covarrubias is an Assistant Professor in the Department of Microbiology, Immunology & Molecular Genetics. He is a first-generation college graduate and Latino scientist hailing from South Los Angeles. He received his Ph.D. from Harvard University and went on to complete his postdoctoral training at UCSF and Buck Institute for Aging Research. His research focuses on understanding the links between metabolism, inflammation, and diseases such as metabolic disease, aging, and cancer. He looks forward to working with MBIDP students to promote an inclusive and supportive environment.

Dr. Anthony Covarrubias will be joining fellow advisor Dr. Claudio Villanueva from UCLA IBP.

 

MIMG Undergraduate Scholars Showcase Their Research

December 5, 2022

MIMG undergraduate scholars had an amazing time showcasing their research and presentation skills at the Fall 2022 MIMG Undergraduate Research Symposium. The Symposium was designed to highlight MIMG students who are doing research in labs at UCLA and also students who took the “Path 1” curriculum,where they learned about conducting research and giving presentations. In short, 19 students presented posters at this session with members of the department and different labs coming to see the great work that is being done by our undergraduates.

 

Dr. Elaine Hsiao Listed Among 40 UCLA scholars as a Highly Cited Researcher by Clarivate

November 15, 2022 (reposted from UCLA Newsroom)

Thirty-nine UCLA faculty members were named among world’s most influential researchers in the sciences and social sciences today.

The Highly Cited Researchers list, compiled annually by analytics firm Clarivate, identifies scholars whose work has been cited most often in papers published by other researchers in their fields over the past decade. Those chosen for the 2022 list have authored studies that rank in the top 1% in the number of scholarly citations worldwide. Several UCLA scholars were among the most highly cited researchers in more than one of the list’s 22 research categories.

“The Highly Cited Researchers list identifies and celebrates exceptional individual researchers at UCLA who are having a significant impact on the research community as evidenced by the rate at which their work is being cited by their peers,” said David Pendlebury, head of research analysis at the Institute for Scientific Information at Clarivate. “These individuals are helping to transform human ingenuity into our world’s greatest breakthroughs — and it is an honor to celebrate their achievements.”

Elaine Hsiao, integrative biology

 

Dr. Lili Yang’s Cell Therapy Work to Improve Bone Marrow Transplantation Featured on UCLA News

October 28, 2022

The findings identify a potential strategy to make bone marrow transplants safer without disrupting their ability to fight cancer. While the protective effects iNKT cells have against graft-versus-host disease has been observed in patients in the clinic, this discovery has not yielded an available therapy because iNKT cells are so rare. The new study outlines a new method for producing large numbers of iNKT cells from donated cord blood. The researchers estimate one cord blood donation could produce more than 10,000 doses of iNKT cells for clinical use.

To read the full article, please see here: https://newsroom.ucla.edu/releases/cell-therapy-could-improve-bone-marrow-transplant-safety

 

Dr. Lili Yang’s work on iNKT Cells Featured on CIRM Blog

October 28, 2022

Dr. Yang and her team at UCLA have developed stem cell-engineered invariant Natural Killer T (iNKT) cells, a kind of specialized immune system cell, that has the ability to attack and kill a broad range of cancerous cells, while leaving the body’s healthy tissues unharmed.

Thanks to several CIRM grants, Dr. Yang has developed a platform that can use healthy donor blood stem cells to produce clinical scalable “off-the-shelf” iNKT cells. That has led to the creation of Appia Bio, a start-up company, and talks with the FDA about testing a series of iNKT cell products in clinical trials.

To read more, please see the full article here: https://blog.cirm.ca.gov/2022/10/26/developing-a-natural-killer-for-cancer/

 

Dr. Timothy O’Sullivan awarded the ICIS Regeneron Award

October 5, 2022

Our faculty member Tim O’Sullivan was recently awarded the ICIS Regeneron New Investigator Award for Excellence in Research! Much deserved!

 

Graduate Student Andrew Hildreth receives the Dissertation Year Fellowship from the Molecular Biology Institute

October 5, 2022

Andrew Hildreth is a Ph.D. student in Dr. Timothy O’Sullivan’s lab. Congratulations!

 

Biologist Elaine Hsiao named Blavatnik National Award Laureate

 

September 21, 2022

Elaine Hsiao, the De Logi professor of Biological Sciences and an associate professor of integrative biology and physiology in the UCLA College, has been named a 2022 Blavatnik National Awards Laureate in life sciences by the Blavatnik Family Foundation and the New York Academy of Sciences. The award honors Hsiao’s pioneering and interdisciplinary research that connects the gut microbiome and immune system to brain development and behavior.

Hsiao’s research seeks to understand how biomolecules called metabolites produced by gut microbes influence the brain and other parts of the nervous system. Microbes that live harmoniously in our digestive tracts produce metabolites as byproducts of their normal biological functions. Some of these metabolites moderate the levels of neuromodulatory molecules, including neurotransmitters and neuropeptides. Hsiao has shown that changes in the gut microbiome can therefore have far-reaching effects on neurological function and complex behaviors.

The award comes with $250,000, the largest unrestricted scientific award for America’s most innovative, young faculty-ranked scientists and engineers. The Blavatnik National Awards for Young Scientists will celebrate the 2022 laureates and finalists in a ceremony on Sept. 19 at the American Museum of Natural History in New York.

 

$500,000 gift from the Charles Huang Foundation will support research focused on infection, immunity, cancer and metabolism

September 13, 2022

The UCLA Division of Life Sciences has received a $500,000 gift from the Charles Huang Foundation to support the research of Genhong Cheng, a professor in the Department of Microbiology, Immunology and Molecular Genetics and a member of the UCLA Molecular Biology Institute, California NanoSystems Institute at UCLA and the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center.

“Dr. Cheng’s work exemplifies a key mission of our division: exploring the most important scientific questions we face today,” said Tracy Johnson, Dean of Life Sciences at UCLA. “The last few years have clearly illustrated the need to understand the way the immune system works, and Dr. Cheng’s research has far-reaching implications — from understanding infection and inflammation to uncovering new approaches to treating cancer.”

“We are grateful for the Charles Huang Foundation’s gift, which not only supports faculty and their research, but will also help drive innovation in infectious disease and cancer science,” said Jerome Zack, UCLA distinguished professor and MIMG department chair.

“Supporting basic science research is incredibly important,” said Charles Huang, chairman of the Charles Huang Foundation. “We are pleased to support Genhong Cheng, an accomplished faculty member who’s making important strides in cancer research.”

Cheng’s laboratory hopes to understand both the similarities and differences in host immune responses to infections by different types of pathogens. In addition, the lab aims to better appreciate how we balance immune and inflammatory responses, and how these responses influence other homeostatic and metabolic processes, with the ultimate goal of developing novel strategies to enhance our immune system against infections and tumor challenges while preventing or inhibiting inflammatory and metabolic diseases.

“Support from the Charles Huang Foundation will enhance our ability to perform pioneering research, ensure inclusive teaching and accelerate basic discoveries to translation,” said Cheng.

The Charles Huang Foundation was established in 2020 by entrepreneur Charles Huang with a mission to accelerate and encourage education, health-related research and entrepreneurship on a global platform. Through the foundation, Huang has also made substantial donations to the University of Strathclyde in Scotland, Wuhan University in China, the Chinese Hospital in San Francisco and USC Arcadia Hospital in Arcadia.

 

MIMG Faculty Dr. Anthony J. Covarrubias wins 2022 AFAR Junior Faculty Grant Award

September 2, 2022

We are proud to announce that MIMG faculty member Dr. Anthony J. Covarrubias is the latest recipient of the 2022 Junior Faculty Grant Award 🎉🙌

The grant is awarded by the Glenn Foundation for Medical Research and American Federation for Aging Research (AFAR). Please join us in warmly congratulating Dr. Covarrubias!

MIMG Faculty Dr. Lili Yang and Dr. Donald Kohn among UCLA scientists to receive CIRM Quest Awards 

June 27, 2022

Associate Professor of MIMG Lili Yang and Distinguished Professor of MIMG are among a group of UCLA scientists to receive the Quest Award from the Broad Center of Regenerative Medicine and Stem Cell Research (CIRM) for their work in developing novel stem cell-based technologies.

Dr. Yang’s award of $1.4 million will fund her efforts to develop stem cell-engineered off-the-shelf chimeric antigen receptor-invariant natural killer T cells, or CAR-iNKT cells, to treat ovarian cancer, which accounts for more deaths than any other cancer of the female reproductive system. She aims to produce CAR-iNKT cells that target mesothelin, a protein that is found in high levels on the surface of ovarian cancer cells. The proposed immunotherapy builds on Yang’s work to generate blood stem cell-derived CAR-iNKT cells to target multiple myeloma, a project that received funding from CIRM in 2021. Yang will collaborate on this project with Dr. Sanaz Memarzadeh, a UCLA physician-scientist who specializes in ovarian cancer treatment.

Dr. Kohn’s $1.3 million award will support his research to develop a blood stem cell gene therapy to treat severe alpha thalassemia, an inherited blood disorder that causes a patient’s body to make less hemoglobin than normal. Hemoglobin carries oxygen to all parts of the body, so severe alpha thalassemia could lead to fetal death or a lifelong need for blood transfusions. If there is a team capable of creating an ex vivo gene therapy treatment for alpha thalassemia and bringing it to a clinical trial, this is the team, CIRM reviewers said.

For more information, click here.

MIMG Undergraduate Siyah Shah Receives 2022 Philip Whitcome Summer Research Fellowship Award

June 24, 2022 

Please join us in congratulating Siya, who will be conducting biological research with Dr. Timothy O’Sullivan in Summer 2022. 

 

Xinyuan Chen receives 2021-2022 John W. Philips Legacy Award
May 31, 2022
The Department of Microbiology, Immunology, and Molecular Genetics (MIMG) is pleased to announce the 2021-22 John W. Phillips Legacy Award recipient, Xinyuan Chen.
 
Xinyuan Chen is fourth-year doctoral student in Molecular Biology working with Dr. Douglas Black in MIMG. Her research focuses on dissecting the mis-regulation of alternative splicing in Myc-driven prostate cancers. Her work contributes important new understandings of genetic misregulation in cancer. Xinyuan has worked closely with cancer biology experts, Dr. Owen Witte, and also Dr. John W. Phillips, whose memory is honored by this award. According to Xinyuan, “Dr. Phillips has greatly impacted my project and his mentorship motivated me as a graduate student to continue my cancer biology research.” Following in the footsteps of her mentor, Xinyuan is dedicated to teaching and mentoring underrepresented students, and promoting diversity and inclusion in science.
 
Please join us in sharing our gratitude with the Phillips family for the award and congratulating Xinyuan Chen and the other stellar nominees!
 
The John W. Phillips Legacy Award honors the life, work, and principles of Dr. John W. Phillips. The award provides funds to graduate students and continues Dr. Phillips’ support of mentorship of individuals in the field. It recognizes outstanding graduate students in all disciplines included in the Department of Microbiology, Immunology, and Molecular Genetics, including cancer research.
Dr. John W. Phillips was a teacher and mentor in UCLA’s Department of Microbiology, Immunology, and Molecular Genetics who was committed to promoting diversity and equity in the field. Dr. Phillips devoted his considerable brilliance and hard work to cancer research, principally working in the lab of Dr. Owen Witte.
 
Dr. Phillips dedicated his formidable writing talent and passion for teaching to graduate students. He taught graduate students in the lab and he was a mentor to many, with a special emphasis on organizing their science and helping with their writing of paper and grants.
 
To honor his legacy and dedication to advancing diversity and equity, the John W. Phillips Award was established to support outstanding graduate students working in a laboratory within the Department of Microbiology, Immunology, and Molecular Genetics.

MIMG Students Recognized for Phages they Isolated and Characterized

January 18th, 2022

MIMG students in the Path 1 research track publish two articles in PLoS ONE about phages they isolated and characterized, under the supervision of Drs. Amanda Freise, Kris Reddi, and Jordan Moberg Parker. Articles available HERE and HERE.

Lili Yang lab licenses cell-therapy tech to start-up, receives CIRM TRAN1 award, and publishes two papers in Science Immunology and Nature Communications. 

June 16th, 2021

The Yang lab recently published two papers back-in-back on Science Immunology and Nature Communications, reporting the identification of a new immune checkpoint and the repurposing of an old antidepressant for cancer immunotherapy. Details HERE and HERE.

The Yang lab also received CIRM TRAN1 award worth $5.9 million supporting the development of an off-the-shelf CAR-iNKT cell therapy for multiple myeloma. Read more HERE.

Additionally, the Yang lab’s off-the-shelf cell therapy technology was licensed by a biotech startup, Appia Bio, for commercial development. The company recently launched with $52 million Series A financing. You can read more about the licensing agreement HERE.

 

Timothy O’Sullivan receives Excellence in Research Award

June 7th, 2021

Excellence in Research Award for an Untenured Professor
Timothy O’Sullivan – Assistant Professor, Microbiology, Immunology, & Molecular Genetics
Dr. O’Sullivan is awarded for his paper, “ILC1 Confer Early Host Protection at Initial Sites of Viral Infection” Cell 2017. In this impressive paper, Dr. O’Sullivan and colleagues show that a unique subset of immune cells within tissues represents the first line of defense to viral infections. Without this rapid tissue-resident immune cell response, the immune system cannot efficiently control viral replication resulting in more severe infections.